Longevity ⏱ Half-life: Extended compared to L-amino acid peptides due to D-retro-inverso modification. Specific pharmacokinetics not fully characterized. Preclinical

FOXO4-DRI

FOXO4-D-Retro-Inverso Peptide

Updated March 15, 2026

Evidence at a Glance

Regulatory statusPreclinical
No human trials; foundational 2017 mouse senolytic study plus later rodent and human-cell work only
Human evidenceNone
Animal evidenceLimited

FOXO4-DRI is a designed senolytic peptide that cleared senescent cells and improved several aging markers in mice, but it has never been tested in humans and has no clinical safety or dosing data.

What the research does not support

  • It has never been tested in humans; no clinical dosing, pharmacokinetic or safety data exist in people.
  • Its "reverses aging" reputation rests entirely on mouse and cell-culture studies.
  • It is not a proven senolytic therapy — there is no clinical evidence it safely clears senescent cells in humans.
  • Long-term effects, including risks tied to its apoptosis-inducing mechanism, are uncharacterized.
Half-Life
Extended compared to L-amino acid peptides due to D-retro-inverso modification. Specific pharmacokinetics not fully characterized.
Mol. Weight
~5000 g/mol

What is FOXO4-DRI?

FOXO4-DRI represents a precision approach to clearing senescent cells — the “zombie cells” that accumulate with age and drive chronic inflammation and tissue dysfunction. Unlike broad-spectrum senolytics, it specifically targets the molecular mechanism that keeps senescent cells alive.

Research Applications

Senescent cell clearance, aging biology, tissue rejuvenation, kidney function restoration, and senolytic therapy development.

Dosage Information (Research Use)

Mouse research: 5 mg/kg IV, administered three times per week for several weeks. Human dosing not established. Research use only.

Reconstitution & Handling

Reconstitute with sterile water or BAC water. Higher concentrations may be needed due to mg/kg dosing.

Half-Life & Pharmacokinetics

Extended compared to L-amino acid peptides due to D-retro-inverso modification. Specific pharmacokinetics not fully characterized.

Reported Observations in Literature

Mouse studies showed transient weight loss during treatment, with recovery after completion. Selective for senescent cells — should not affect healthy tissue.

Key Research References

  • Baar MP, et al. “Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging.” Cell. 2017

How FOXO4-DRI Works

FOXO4-DRI works by disrupting the interaction between FOXO4 and p53 in senescent cells. In these cells, FOXO4 sequesters p53 in the nucleus, preventing p53 from triggering apoptosis — essentially keeping 'zombie cells' alive. FOXO4-DRI competes for this binding, releasing p53 to activate cell death specifically in senescent cells while sparing healthy cells. The D-retro-inverso modification uses D-amino acids in reversed sequence to resist proteolytic degradation while maintaining target binding.

Research Findings

Published in Cell (2017): restored fitness, fur density, and renal function in aged mice. One of the most targeted senolytic approaches, affecting only cells with elevated FOXO4-p53 interaction. Cost and complexity limit widespread research use.

Dosage & Administration

Mouse research: 5 mg/kg IV, administered three times per week for several weeks. Human dosing not established. Research use only.

Safety & Side Effects

Mouse studies showed transient weight loss during treatment, with recovery after completion. Selective for senescent cells — should not affect healthy tissue.

Important: All safety information is derived from published research, primarily animal studies. No controlled human clinical trial data exists unless explicitly noted. This compound is sold for research purposes only.

Quick Facts

Sequence D-retro-inverso modified FOXO4 peptide
Molecular Weight ~5000 g/mol
Half-Life Extended compared to L-amino acid peptides due to D-retro-inverso modification. Specific pharmacokinetics not fully characterized.
Available Sizes 5mg, 10mg
Storage Lyophilized: -20°C. Reconstituted: 2-8°C.

Key Research References

  • Baar MP, et al. "Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging." Cell. 2017

Related Peptides

View all →
Pancragen
Longevity
Tetrapeptide bioregulator studied for pancreatic tissue support and glucose metabolism regulation.
View Profile →
Glutathione
Longevity
The body's master antioxidant — a tripeptide critical for detoxification, oxidative stress defense, and cellular health.
View Profile → Buy Now
L-Carnosine
Longevity
Naturally occurring dipeptide with potent anti-glycation, antioxidant, and anti-aging properties found in muscle and brain tissue.
View Profile →